Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06896734 · ClinicalTrials.gov registry record
mobiCARE™ ECG Monitoring System
A clinical trial of ECG Monitoring, sponsored by Seers Technology Co..
- Completed
- Registry status
- 49
- Enrollment target
- 1
- Study location
NCT06896734: Completed study of ECG Monitoring, sponsored by Seers Technology Co..
NCT06896734 is a study of ECG Monitoring that has completed, run by Seers Technology Co.. The registered enrollment target is 49 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06896734, a study of ECG Monitoring, has completed, sponsored by Seers Technology Co..
- COMPLETED
- Registry status
- 49 participants
- Enrollment target
- 1
- Study location
Study Summary
Evaluation of the mobiCARE™ ECG Monitoring System Electrode Placement Positioning Limits in a Prospective, Non-Randomized, Single-Center U.S. Study
Primary Outcome
Evaluation of the ECG signal at the nominal location and in up to three (3) additional alternate positions (AP) in each subject to determine if the signal is interpretable. The term "interpretable" is defined as follows: An independent cardiologist reader is able to identify the ECG rhythm in each location when compared to the ECG rhythm measured in the nominal position of the mobiCARE™ Cardiac Monitoring System described in the Instructions for Use. ECG rhythm data will be collected for up to t
Conditions Studied
Interventions
- DEVICE Evaluation of the ECG signal in the nominal location and in three alternate positions
Study Locations (1)
Colorado
- MCB Clinical Research Centers, LLC - Colorado Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2025-01-01 |
| Est. Completion | 2025-03-16 |
What the finished NCT06896734 record still lists
NCT06896734 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 49 participants, a relatively small participant target.
The record links to 1 condition, with ECG Monitoring appearing as the primary indexed condition, and to 1 intervention - of which Evaluation of the ECG signal in the nominal location and in three alternate positions is the first listed.
NCT06896734 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT06896734 about?
NCT06896734 is a clinical study titled "mobiCARE™ ECG Monitoring System". Evaluation of the mobiCARE™ ECG Monitoring System Electrode Placement Positioning Limits in a Prospective, Non-Randomized, Single-Center U.S. Study
What is the current status of trial NCT06896734?
This trial is currently completed. The enrollment target is 49 participants. The study started on 2025-01-01. Estimated completion is 2025-03-16.
What conditions does trial NCT06896734 study?
This clinical trial studies the following conditions: ECG Monitoring.
What interventions are being tested in trial NCT06896734?
The interventions under investigation include: Evaluation of the ECG signal in the nominal location and in three alternate positions (DEVICE).
Who is sponsoring clinical trial NCT06896734?
This trial is sponsored by Seers Technology Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06896734 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI